701 related articles for article (PubMed ID: 14679270)
1. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
3. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
4. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
5. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
Ortonne JP; Shear N; Shumack S; Henninger E;
BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
[TBL] [Abstract][Full Text] [Related]
6. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
[TBL] [Abstract][Full Text] [Related]
7. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
8. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
9. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
18. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
19. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]